A Monoclonal Antibody against 6-Acetylmorphine Protects Female Mice Offspring from Adverse Behavioral Effects Induced by Prenatal Heroin Exposure

Anne Marte Sjursen Kvello, Jannike Mørch Andersen, Elisabeth Leere Øiestad, Synne Steinsland, Audun Aase, Jørg Mørland, and Inger Lise Bogen

Section for Drug Abuse Research, Department of Forensic Sciences, Oslo University Hospital, Oslo, Norway (A.M.S.K., J.M.A., E.L.O., S.S., I.L.B.); School of Pharmacy, Faculty of Mathematics and Natural Sciences (A.M.S.K., J.M.A., E.L.O.), Institute of Basic Medical Sciences (I.L.B.) and Institute of Clinical Medicine (J.M.), Faculty of Medicine, University of Oslo, Oslo, Norway; and Department of Infectious Disease Immunology (A.A.) and Department of Health Data and Digitalization (J.M.), Norwegian Institute of Public Health, Oslo, Norway

Received June 19, 2018; accepted October 22, 2018

ABSTRACT
Escalating opioid use among fertile women has increased the number of children being exposed to opioids during fetal life. Furthermore, accumulating evidence links prenatal opioid exposure, including opioid maintenance treatment, to long-term negative effects on cognition and behavior, and presses the need to explore novel treatment strategies for pregnant opioid users. The present study examined the potential of a monoclonal antibody (mAb) targeting heroin’s first metabolite, 6-acetylmorphine (6-AM), in providing fetal protection against harmful effects of prenatal heroin exposure in mice. First, we examined anti-6-AM mAb’s ability to block materno-fetal transfer of active metabolites after maternal heroin administration. Next, we studied whether maternal mAb pretreatment could prevent adverse effects in neonatal and adolescent offspring exposed to intrauterine heroin (3 × 1.05 mg/kg). Anti-6-AM mAb pretreatment of pregnant dams profoundly reduced the distribution of active heroin metabolites to the fetal brain. Furthermore, maternal mAb administration prevented hyperactivity and drug sensitization in adolescent female offspring prenatally exposed to heroin. Our findings demonstrate that passive immunization with a 6-AM-specific antibody during pregnancy provides fetal neuroprotection against heroin metabolites, and thereby prevents persistent adverse behavioral effects in the offspring. An immunotherapeutic approach to protect the fetus against long-term effects of prenatal drug exposure has not been reported previously, and should be further explored as prophylactic treatment of pregnant heroin users susceptible to relapse.

Introduction

Opioid use among fertile women has escalated dramatically in recent years, leading to an increased number of children being exposed to opioids during pregnancy (McQueen and Murphy-Oikonen, 2016; Terplan, 2017). While the use of prescription and designer opioids is rising, especially in North America, heroin still remains the most commonly abused illicit drug use (White and Lopatko, 2007; Minozzi et al., 2019). The recommended treatment of heroin-dependent pregnant women is opioid maintenance treatment with methadone or buprenorphine, which successfully reduces morbidity and illicit drug use (White and Lopatko, 2007; Minozzi et al., 2019; White and Lopatko, 2007; Minozzi et al., 2019; White and Lopatko, 2007; Minozzi et al., 2019; White and Lopatko, 2007; Minozzi et al., 2019).

This work was supported by the Research Council of Norway [Grant 213751].

https://doi.org/10.1124/jpet.118.251504.

ABBREVIATIONS: 6-AM, 6-acetylmorphine; ADHD, attention deficit hyperactivity disorder; DAMGO, [D-Ala²,N-Me-Phe⁴,Gly-ol⁵]-enkephalin; E, embryonic day; ELISA, enzyme-linked immunosorbent assay; LC-MSMS, liquid chromatography-tandem mass spectrometry; mAb, monoclonal antibody; M3G, morphine-3-glucuronide; P, postnatal day; USV, ultrasonic vocalization.
mAb Protects Offspring against Prenatal Heroin Exposure

2013). However, as for other opioids, maternal opioid maintenance treatment has been shown to induce harmful effects in both human and animal offspring (Farid et al., 2008; Fodor et al., 2014). To avoid opioid maintenance treatment–induced insult to the developing fetus, new treatment options for pregnant heroin users should be explored. A potential novel approach is antidrug immunotherapy, which is based on specific antibodies sequestering the drug in the blood, thereby preventing drug distribution to the brain (Zalewska-Kaszubska, 2015). Antidrug immunotherapy entails active vaccination, which exploits the organism’s own immune system to trigger antibody production, or passive immunization with injection of preformed monoclonal antibodies (mAbs) (Janda and Treweek, 2012).

Immuno-gene against heroin was demonstrated as a proof of concept decades ago (Bonese et al., 1974; Killian et al., 1978), and subsequently a number of active and passive vaccines have been developed and tested against heroin effects in adult rodents (Stowe et al., 2011; Pravetoni et al., 2012; Raleigh et al., 2014; Sulima et al., 2018). We recently examined the properties of a mAb specifically targeting heroin’s first metabolite, 6-acetylmorphine (6-AM) (Bogen et al., 2014; Kvello et al., 2016), which together with morphine is considered a major contributor to heroin-induced effects (Umans and Inturrisi, 1981; Andersen et al., 2009). Passive immunization with anti-6-AM mAb dose dependently reduced heroin-induced psychomotor activation and brain levels of 6-AM and morphine in adult male mice (Bogen et al., 2014; Kvello et al., 2016). While maternal immunization for fetal protection against nicotine, methamphetamine, and phencyclidine has been investigated in rats (Keyler et al., 2003, 2005; Hubbard et al., 2011a; White et al., 2014), maternal immunization against heroin has not been reported previously. Furthermore, former studies have primarily assessed materno-fetal drug distribution, whereas immunotherapeutic protection against long-term effects of prenatal drug exposure has not been explored.

In the present study, we hypothesized that anti-6-AM mAb administered to pregnant mice protects the offspring from harmful effects of intrauterine heroin exposure. To address this, we first examined the ability of the mAb to reduce transfer of active heroin metabolites to the fetus upon heroin administration to pregnant mice. Next, we assessed the efficacy of maternal mAb administration to counteract adverse effects in neonatal and adolescent offspring induced by repeated prenatal heroin exposure. Through these experiments, we aimed to demonstrate that maternal anti-6-AM mAb pretreatment could prevent persistent heroin-induced changes in the developing fetal brain.

Materials and Methods

Animals

Time-mated female C57BL/6J mice arriving on embryonic day (E) 8 (E8; experiment II) or 14 (E14; experiment I) (10–12 weeks old, 20–33 g; Janvier Laboratories, Saint-Berthevin, France) were housed from two to four per cage in the animal facility at the Norwegian Institute of Public Health (Oslo, Norway). The pregnant females were acclimatized for at least 5 days prior to the experiments. In experiment II, maternal weight was registered on E11, E14, and E17. From E18, pregnant females were housed individually, and disturbance to the females and their offspring was kept to a minimum during the first two postnatal weeks. Temperature, humidity, and light were regulated (22 ± 1°C, 50% ± 10% humidity, light period 7 AM to 7 PM), and commercial mouse pellets and water were available ad libitum. The behavioral experiments were conducted during the light cycle of the day under dimmed lighting. All experimental protocols were approved by the Norwegian Animal Research Authority (Norwegian Food Safety Authority, Oslo, Norway).

Materials

Heroin-HCl (421.91 mol. wt.) was purchased from Lipomed AG (Arlesheim, Switzerland) and dissolved in 0.9% saline. Anti-6-AM mAb (human IgG1) was produced in stable, transfected Chinese hamster ovary cells (clone 214) provided by Affitech Research AS (Oslo, Norway), as described in more detail previously (Moghaddam et al., 2003). In short, the Chinese hamster ovary cells were grown in HyClone SFM4CHO-Utility Medium (WWR, Oslo, Norway) in Integra CELLine CL-1000 in vitro units (BioNordika, Oslo, Norway). The supernatants were harvested twice a week and fractionated by gel filtration on a HiLoad Superdex 200 column (Pharmacia Fine Chemicals, Uppsala, Sweden). The IgG peaks were collected and concentrated by Amicon Ultra-15 centrifugal filters and subsequently passed through a Pierce High Capacity Endotoxin Removal Resin column (ThermoFisher, Oslo, Norway) to remove endotoxins. Finally, the mAb was diluted in 0.9% saline and stored at -80°C. The properties of the anti-6-AM mAb have been described previously (Bogen et al., 2014; Kvello et al., 2016). Opioid doses were chosen based on previous pharmacokinetic and behavioral studies in mice (Andersen et al., 2009; Bogen et al., 2014; Kvello et al., 2016), while mAb doses were chosen based on opioid:mAb ratio experiments reported in Kvello et al. (2016).

Experiment I. The Effect of Anti-6-AM mAb Pretreatment on Maternal Drug Response and Materno-Fetal Distribution of Heroin Metabolites

The Effect of mAb Pretreatment on Heroin-Induced Locomotor Activity in Pregnant Dams (E12). Drug-naive pregnant mice (E11) were randomly assigned to three different treatment groups: saline, heroin, and mAb + heroin. The heroin group (n = 10) received saline pretreatment (0.9%, s.c.) on E11, followed by heroin injection (2.5 μmol/kg; 1.05 mg/kg, s.c.) on E12, 24 hours after the pretreatment. The mAb + heroin group (n = 12) received anti-6-AM mAb pretreatment (50 mg/kg, s.c.) on E11 followed by heroin injection (2.5 μmol/kg, s.c.) on E12. The saline group (n = 11) received saline injections (0.9%, 10 mg/kg, s.c.) on both E11 and E12.

The dams were habituated individually in activity chambers for 60 minutes prior to the injection on E12. Immediately after injection (t = 0 minutes), each mouse was quickly returned to its respective activity chamber for recording of locomotor activity for 90 minutes. The locomotor activity was recorded in Plexiglas chambers (20 × 20 cm) using a Versamax optical animal activity monitoring system (AccuScan Instruments Inc., Columbus, OH) as previously described (Andersen et al., 2009).

Blood and Brain Sampling from Pregnant Dams and Fetuses for Opioid and Antibody Concentration Analyses. Drug-naive pregnant mice (E17) were randomly assigned to two groups: heroin and mAb + heroin. The heroin group (n = 10) received saline pretreatment (0.9%, s.c.) on E17, followed by heroin injection (2.5 μmol/kg, s.c.) 24 hours later on E18. The mAb + heroin group (n = 10) received anti-6-AM mAb pretreatment (50 mg/kg, s.c.) on E17, followed by heroin injection (2.5 μmol/kg, s.c.) on E18. Blood and brain samples were collected from pregnant dams and fetuses 10 and 25 minutes after heroin injection. Blood sampling was performed as follows: pregnant dams were anesthetized with isoflurane 2 to 3 minutes prior to blood sampling by heart puncture using a syringe needle prefilled with 80 μl heparin (100 IU/ml). Blood samples (100 μl) for opioid analysis were transferred to 5 ml tubes containing 100 μl ice-cold ammonium formate buffer (5 mM, pH 3.1) with sodium fluoride.
(4 mg/ml) and quickly frozen in liquid nitrogen. Immediately following blood sampling from the dam, the embryonic sacs containing the fetuses were opened and fetuses were immediately decapitated. Trunk blood from three fetuses per litter was collected using a syringe needle prefilled with 20 μl heparin (100 IU/ml) and pooled into one Eppendorf tube. Fifty microliters of the pooled fetal blood was transferred to 5 ml tubes containing 50 μl ice-cold ammonium formate buffer (5 mM, pH 3.1) with sodium fluoride (4 mg/ml). The blood samples were stored at −80°C until opioid analysis by liquid chromatography–tandem mass spectrometry (LC-MSMS) performed within 24 hours. The remaining blood was immediately frozen in liquid nitrogen and stored at −80°C until antibody IgG1 quantification by enzyme-linked immunosorbent assay (ELISA). Brain sampling was performed as follows: after blood sampling and cervical dislocation of the dams, the cerebrum was quickly removed, washed in ice-cold 0.9% saline solution, and blotted on filter paper. Brain tissue was homogenized (4 ml/g tissue) in ice-cold ammonium formate buffer (5 mM, pH 3.1) containing sodium fluoride (4 mg/ml). Duplicates of 200 μl brain homogenate were transferred to 5 ml plastic tubes and immediately frozen in liquid nitrogen. Fetals brains were collected individually from three fetuses per litter, immediately after decapitation. Each brain was homogenized in 300 μl ice-cold ammonium formate buffer (5 mM, pH 3.1) containing sodium fluoride (4 mg/ml). Duplicates of 100 μl brain homogenate were transferred to 5 ml plastic tubes and quickly frozen in liquid nitrogen. Brain homogenates were stored at −80°C until opioid analysis by LC-MSMS performed within 24 hours.

**Antibody Quantification in Blood.** Blood samples from anti-6-AM mAb pretreated dams (n = 5) and fetuses (n = 8) were diluted in distilled water and analyzed for human IgG1 using a NOVEX ELISA kit (Thermo Fisher Scientific Inc., Waltham, MA). Absorbance was measured (450 nm) using an ELX808 Absorbance Microplate Reader (BIO-TEK Instruments Inc., Winooski, VT).

**Experiment II. Maternal Anti-6-AM mAb Pretreatment as Protection against Prenatal Heroin Exposure in Neonatal and Adolescent Offspring**

**Prenatal Exposure to Heroin (E11–E18).** Drug-naive pregnant mice (E11) were randomly assigned to three groups: saline, heroin, and mAb + heroin. Mice in the saline group (n = 11) received s.c. saline injections (0.9%) on E11, E12, E14, E15, E17, and E18. Mice in the heroin group (n = 10) received s.c. saline injections on E11, E14, and E17 and single s.c. heroin injections (2.5 μmol/kg) on E12, E15, and E18. Mice in the mAb + heroin group (n = 12) received s.c. mAb injections on E11 (50 μg/kg), E14 (10 μg/kg), and E17 (10 μg/kg), and single s.c. heroin injections (2.5 μmol/kg) on E12, E15, and E18. An overview of the treatment groups, timeline for injections during pregnancy, and experimental procedures performed in offspring are described in Fig. 3.

**Ultrasonic Vocalization in Neonatal Mice.** Ultrasonic vocalization (USV) was measured in individual offspring (n = 26–34 from each treatment group) on postnatal dayting (P) until viviparity (i.e., P1). The pups were weighed and isolated from their mother and littersmates for 15–20 minutes by placing them in a separate cage with regulated heating. The recordings of USV were conducted in a separate room, where each pup was placed individually in a Plexiglas cage with regulated heating and an ultrasound microphone (UltraVox 3.0; Noldus Information Technology, Wageningen, The Netherlands) was attached 15 cm above the animal. Vocalizations in the 50–100 kHz range were recorded for 6 minutes using UltraVox XT 3.0 software (Noldus Information Technology). After recording, the pup was immediately returned to its home cage.

**Sampling of Blood and Brain Tissue from Neonatal Mice.** Three pups per litter were sacrificed by decapitation on P1. Immediately after decapitation, trunk blood was collected from individual mice using a syringe needle prefilled with 10 μl heparin (100 IU/ml). Whole blood samples were quickly frozen in liquid nitrogen and stored at −80°C until quantification of corticosterone. Immediately following blood sampling, the brains were collected and frozen in liquid nitrogen. Brain samples were stored at −80°C until opioid receptor binding studies.

**Opioid Receptor Binding.** Brains collected from mice on P1 (n = 9–15 for each treatment group) wereweighed, thawed, and homogenized (glass-Teflon, 2000 rpm, 40 seconds) in ice-cold incubation buffer (20 μl/g, pH 7.4) containing 50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 0.5 mM MgCl2. Whole brain homogenate was centrifuged for 30 minutes (3,000g, 4°C) and the supernatant discarded. The pellet was resuspended in incubation buffer and incubated for 30 minutes at 37°C to remove endogenous opioids. The suspension was centrifuged for 30 minutes (3,000g, 4°C) and the resulting pellet was resuspended in incubation buffer. Samples were aliquoted and stored at −80°C.

Whole brain homogenate samples (duplicates) were preincubated (10 minutes, 25°C) before incubation for 60 minutes (25°C) with 2 nM [3H] DAMGO ([D-Ala2, N-Me-Phe4, Gly-ol5]-Enkephalin; PerkinElmer, Oslo, Norway) (final volume 200 μl). Nonspecific binding was determined by adding 10 μM naloxone to parallel samples. The binding reaction was terminated by dilution with ice-cold 50 mM Tris-HCl (pH 7.4) and rapid filtration through GF/B glass microfiber filters (25 mm; VWR) pretreated for 60 minutes in 0.5% polyethyleneimine solution. The filters were washed three times, and 4 ml UltimaGold was added to each filter before radioactivity counting in a liquid scintillation analyzer (Tri-Carb 2810TR, PerkinElmer). Specific receptor binding was calculated as total minus nonspecific binding, and then converted to the amount of [3H]DAMGO bound per milligram tissue protein (femtomoles per milligram). Protein content was measured as previously described (Lowery et al., 1951).

**Corticosterone Quantification in Blood from Neonatal Mice.** Blood samples from P1 offspring (n = 9–15 for each treatment group) were thawed and diluted in assay sample buffer and analyzed for mouse corticosterone using a competitive ELISA kit (Thermo Fisher Scientific, Inc.). Absorbance was measured (450 nm) using an ELX808 Absorbance Microplate Reader (BIO-TEK Instruments Inc.).

**Locomotor Activity in Adolescent Mice.** Heroin-induced locomotor activity in adolescent mice prenatally exposed to saline (n = 8 males; n = 11 females), heroin (n = 8 males; n = 9 females), or mAb + heroin (n = 12 males; n = 14 females), was measured on P28 according to the procedure described in experiment I. Locomotor activity during the habituation phase (60 minutes) was recorded to measure the animals’ basal activity in a novel environment. Immediately after habituation, each mouse was given a heroin injection (1.5 μmol/kg, equivalent to 0.7 mg/kg, s.c., t = 0 minutes), and quickly returned to its respective activity chamber where locomotor activity was recorded for 20 minutes.

**Blood and Brain Sampling from Adolescent Mice for Opioid and Antibody Quantification.** Immediately after the locomotor activity test, the mice were transferred from the activity chambers to a separate room and sacrificed for sampling of brain tissue for opioid quantification and blood sampling for human IgG1 quantification. Blood sampling was performed as follows: mice (n = 7) from the mAb + heroin group were anesthetized with isoflurane, and blood was sampled by heart puncture 25 minutes after heroin injection using a syringe needle prefilled with 80 μl heparin (100 IU/ml). Whole blood samples were quickly frozen in liquid nitrogen and stored at −80°C until antibody quantification by ELISA, performed as described in experiment I. Brain sampling was performed as follows: after cervical
dislocation, the cerebrum was quickly removed from all animals included in the locomotor activity test (P28), washed in ice-cold 0.9% saline solution, and blotted on filter paper. The brain tissue was homogenized and analyzed for heroin metabolites as described in experiment I.

Data and Statistical Analysis. Data are presented as mean ± S.E.M. unless stated otherwise. For comparison between two groups, the Student’s t test was used. One-way analysis of variance was performed for comparison of the three treatment groups (saline, heroin, and mAb + heroin) with a significant F value followed by Tukey’s post hoc test. Values of P < 0.05 were considered statistically significant. Statistical tests were performed using SPSS version 23 (SPSS Inc., Chicago, IL). USV data were analyzed using UltraVox XT 3.0 software (Noldus Information Technology). The figures and tables were generated using GraphPad Prism version 7 (GraphPad Software, Inc., San Diego, CA).

Results

Experiment I. The Effect of Anti-6-AM mAb Pretreatment on Maternal Drug Response and Materno-Fetal Distribution of Heroin Metabolites

Anti-6-AM mAb Pretreatment Reduced Heroin-Induced Locomotor Activity in Pregnant Mice. We have previously reported that heroin induces locomotor activity in a dose-dependent manner in male mice (Andersen et al., 2009), and that this response can be inhibited by anti-6-AM mAb pretreatment (Bogen et al., 2014; Kvello et al., 2016). Here, we tested the effect of mAb pretreatment on heroin-induced locomotor activity in pregnant mice on E12. A single heroin injection caused a rapid increase in locomotor activity, reaching $E_{\text{max}}$ after 10 minutes (2646 ± 265 cm per 5 minutes, Fig. 1A). Pregnant mice pretreated with mAb displayed a significant decrease in heroin-induced locomotor activity ($P < 0.05$ at 10–55 minutes, Fig. 1A), with a 62% reduction in total run distance compared with mice in the heroin group ($P < 0.05$, Fig. 1B). There was no difference between groups in baseline locomotor activity during habituation, and saline injection did not induce changes in locomotor activity (Fig. 1). Locomotor activity testing was initially planned also on E15 and E18; however, preliminary experiments revealed large individual differences in the animals’ capability to engage in running activity at this stage of pregnancy.

Maternal Anti-6-AM mAb Pretreatment Decreased the Transfer of Active Heroin Metabolites to Fetal Blood and Brain. Pregnant mice were pretreated with mAb or saline 24 hours before a single heroin injection on E18 (2.5 µmol/kg, corresponding to 1.05 mg/kg). The total concentration (free and mAb bound) of the heroin metabolites 6-AM, morphine, and M3G were measured in maternal and fetal blood and brain samples 10 and 25 minutes after heroin injection to dams. Heroin was not quantified since it is rapidly converted to 6-AM and becomes undetectable both in blood and brain within 10 minutes after injection in mice (Andersen et al., 2009; Kvello et al., 2016). The fetal blood concentration of 6-AM after heroin injection to dams was low compared with maternal blood concentrations (Fig. 2, A and D), while morphine concentrations were within the same range (Fig. 2, B and E). Essentially no M3G was detected in the fetus (Fig. 2F), possibly explained by the low levels of the enzyme Uridine 5’-diphosphoglucuronosyltransferase (UGT) prior to birth (Fyffe and Dutton, 1975), which may contribute to poor fetal elimination of morphine. Maternal mAb pretreatment did not affect either maternal or fetal blood 6-AM or M3G concentrations. Blood morphine concentrations in mAb-pretreated mice were reduced compared with the heroin group, as observed at both 10 and 25 minutes in maternal blood and at 10 minutes in fetal blood ($P < 0.05$, Fig. 2, B and E).

After heroin injection to dams, the 6-AM concentration in fetal brain was 31%–40% of the levels measured in maternal brain (Fig. 2, G and I), while morphine concentrations were 45% (10 minutes) and 129% (25 minutes) of maternal brain concentrations (Fig. 2, H and J). Fetuses from dams pretreated with mAb had 6-AM levels reduced by 55% and 89% at 10 and 25 minutes after heroin injection, respectively, compared with fetuses in the heroin group ($P < 0.001$, Fig. 2I). mAb pretreatment also reduced fetal brain morphine concentrations by 92% (10 minutes) and 37% (25 minutes) ($P < 0.05$, Fig. 2J). Compared with brain 6-AM levels measured in dams from the heroin group, mAb pretreatment reduced maternal brain 6-AM levels by 48% and 71% at 10 and 25 minutes after heroin injection, respectively ($P < 0.05$, Fig. 2G), and brain morphine levels by 46% at 10 minutes and 51% at 25 minutes ($P < 0.05$, Fig. 2H). M3G was not detected in either maternal or fetal brain tissue.

The Anti-6-AM mAb Levels in Fetal Blood Were One-Fourth of the Levels in Maternal Blood. The anti-6-AM mAb employed in the current study belongs to the human IgG1 subclass and was measured in maternal and fetal blood on E18, 24 hours after mAb injection. The dams had an average blood concentration of 303 ± 8 µg/ml, while
70 ± 5 μg/ml was detected in fetal blood, comprising 23% of the IgG1 level detected in the dams.

Experiment II. Maternal Anti-6-AM mAb Pretreatment as Protection against Adverse Effects of Prenatal Heroin Exposure in Neonatal and Adolescent Offspring

The results from experiment I revealed that maternal anti-6-AM mAb pretreatment reduced the distribution of active heroin metabolites to the fetal brain. In a second set of experiments, we therefore examined the effects of maternal mAb treatment on the outcome in neonatal and adolescent offspring after intermittent prenatal exposure to heroin. Pregnant mice were administered three single injections of heroin with a 3-day interval during late gestation (2.5 μmol/kg on E12, E15, and E18), with or without mAb pretreatment, and the effects were examined in neonatal pups (P1) and adolescent mice (P28) (see the outline in Fig. 3).

Maternal Weight Gain, Neonatal Weight, and Litter Size Were Not Affected by Heroin or Anti-6-AM mAb Pretreatment during Pregnancy. We measured maternal weight gain during pregnancy, average neonatal weight (P1), and litter size after prenatal exposure to saline, heroin, or mAb + heroin, and found no significant differences between the treatment groups (Table 1).

Neonatal Offspring Prenatally Exposed to Heroin Did Not Show Significant Withdrawal Symptoms. Neonatal offspring born to opioid-exposed mothers commonly

Fig. 2. (A–J) Maternal and fetal opioid concentrations measured 10 and 25 minutes after heroin injection (2.5 μmol/kg, s.c.) to pregnant dams (E18) pretreated with saline or anti-6-AM mAb (50 mg/kg, s.c.) on E17. Maternal blood and brain (n = 5), fetal brain (n = 15 from 5 litters), and fetal blood (n = 5–8, each blood sample pooled from three fetuses). Values are mean + S.E.M., *P < 0.05; **P < 0.01; ***P < 0.005, Student’s t test.

Fig. 3. Timeline for injections in pregnant dams and experiments in offspring (experiment II). Her, heroin; mAb10/50, anti-6-AM mAb 10 or 50 mg/kg; Sal, saline.
show withdrawal symptoms, which can be measured as increased USV or elevated levels of stress hormones in rodents (Neal and Sparber, 1986; Barr et al., 2011). In addition, altered μ-opioid receptor density in neonatal rodent brain has been reported after prenatal opioid exposure (Tempel et al., 1988; Bhat et al., 2006). We measured USV, blood corticosterone concentration, and whole brain μ-opioid receptor expression in 1-day-old pups prenatally exposed to saline, heroin, or mAb + heroin, and found no significant differences between the treatment groups (Fig. 4).

Maternal Anti-6-AM mAb Pretreatment Protects against Heroin-Induced Locomotor Sensitization in Adolescent Females Prenatally Exposed to Heroin. To determine whether exposure to heroin during pregnancy could induce a sensitized drug response in adolescent offspring, and whether maternal mAb pretreatment could protect from this effect, adolescent mice were tested for heroin-induced locomotor activity on P28. Both males and females from all treatment groups displayed a marked increase in locomotor activity after a single injection of heroin (1.5 μmol/kg, Fig. 5, A and B). The total run distance in female offspring prenatally exposed to heroin was doubled compared with females prenatally exposed to saline (P < 0.05, Fig. 5B). This heroin-induced locomotor sensitization was absent in females from mAb pretreated mothers, and their locomotor activity was reduced by 34% (P = 0.06) compared with female offspring in the heroin group (Fig. 5B). Male adolescent offspring prenatally exposed to heroin did not express a sensitized heroin-induced behavioral response, and no differences in locomotor activity were found between the male treatment groups (Fig. 5, D and E).

To examine whether the changes in behavioral response could be explained by differences in brain opioid levels, brain tissue was collected immediately after the locomotor activity test and analyzed for the heroin metabolites 6-AM and morphine. Brain opioid concentrations were within the same range in females and males from all treatment groups (Fig. 5, C and F); although a slight nonsignificant tendency of decreased levels was observed in females from the mAb + heroin group (Fig. 5C). Remaining anti-6-AM mAb was therefore assessed in blood from adolescent mice prenatally exposed to mAb, and negligible levels of human IgG1 (5.5 ± 1.0 μg/ml) were detected. This is in accordance with the mAb’s estimated biologic half-life of 8 to 9 days in mice (Bogen et al., 2014).

Maternal Anti-6-AM mAb Pretreatment Protects against Hyperactivity in Adolescent Females Prenatally Exposed to Heroin. Baseline locomotor activity in a novel environment was assessed prior to testing of drug-induced psychomotor activity in adolescent mice. The total activity recorded in adolescent females prenatally exposed to heroin was increased by 31% compared with females prenatally exposed to saline (P < 0.01, Fig. 6A). The locomotor activity of female offspring exposed to mAb + heroin was not significantly different from either the saline controls or the heroin-exposed group. For male offspring, no differences in activity upon novelty were observed between groups (Fig. 6B).

Discussion

Our findings provide evidence that passive immunization with a monoclonal antibody during pregnancy may serve as a useful approach to protect the developing fetus from adverse heroin effects. Maternal pretreatment with anti-6-AM mAb markedly reduced the distribution of active heroin metabolites to the fetal brain upon heroin administration to pregnant mice. Furthermore, maternal mAb administration prevented adverse behavioral effects in female adolescent mice induced by intrauterine heroin exposure, suggesting efficient protection against persistent changes in the fetal brain. To our knowledge, the present study is the first to demonstrate that mAb pretreatment during pregnancy mediates offspring protection from long-term effects caused by prenatal drug exposure.

Lipophilic drugs such as heroin and its metabolites can easily transverse the placental barrier and distribute to fetal tissues upon maternal drug administration (Hartvig et al., 1989; Pichini et al., 2005). Heroin is considered a prodrug with

### Table 1
Average weight gain in pregnant dams from embryonic days 11–17, litter size and pup weight on postnatal day 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Weight Gain in Dams (E11-17)</th>
<th>Litter Size</th>
<th>Pup Weight (P1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>7.99 ± 0.35</td>
<td>6.36 ± 0.39</td>
<td>1.32 ± 0.02</td>
</tr>
<tr>
<td>Heroin</td>
<td>8.26 ± 0.46</td>
<td>6.10 ± 0.38</td>
<td>1.30 ± 0.02</td>
</tr>
<tr>
<td>mAb + heroin</td>
<td>8.09 ± 0.29</td>
<td>6.50 ± 0.34</td>
<td>1.32 ± 0.02</td>
</tr>
</tbody>
</table>

a n = 10–12.

b n = 26–46.
effects mediated mainly by the metabolites 6-AM and morphine. Therefore, we hypothesized that administration of a mAb specifically targeting 6-AM to pregnant mice would protect the fetus from harmful heroin effects by inhibiting transfer of active heroin metabolites to the fetal brain. Indeed, the anti-6-AM mAb significantly reduced fetal 6-AM brain levels by up to 89%. Although the anti-6-AM mAb does not bind morphine, fetal brain levels of morphine were also reduced, indicating indirect fetal neuroprotection against morphine effects as well. In previous studies using immunotherapy against heroin, we and others have shown that sequestration of heroin’s first metabolite, 6-AM, is crucial to prevent heroin-induced effects in adult rodents (Bogen et al., 2014; Raleigh et al., 2014; Kvello et al., 2016). Our current findings demonstrate that maternal anti-6-AM mAb administration provides efficient fetal neuroprotection by inhibiting distribution of active heroin metabolites to the fetal brain.

The endogenous opioid system plays an important role in brain development (McDowell and Kitchen, 1987; Sargeant et al., 2008), and prenatal exposure to exogenous opioids can disturb basic processes such as neuronal differentiation and myelination (Eschenroeder et al., 2012; Vestal-Laborde et al.,

Fig. 5. Behavioral effects of prenatal exposure to saline, heroin, or mAb + heroin in female and male adolescent offspring (P28). (A and D) Heroin-induced (1.5 μmol/kg, s.c.) locomotor activity (cm/5 minutes) during habituation (t = −60 -0 minutes), and after heroin injection (t = 0–20 minutes). (B and E) Total run distance (cm/20 minutes) after heroin injection. (C and F) Brain opioid concentrations measured 25 minutes after heroin injection. n = 8–14 for locomotor activity studies; n = 5–9 for opioid quantification. Values are mean + S.E.M., *P < 0.05 against saline, one-way analysis of variance with Tukey’s post hoc test.

Fig. 6. Locomotor activity (cm/60 minutes) in a novel environment in adolescent (P28) females (A) and males (B) prenatally exposed to saline, heroin, or mAb + heroin. n = 8–13. Values are mean + S.E.M., **P < 0.01 against saline, one-way analysis of variance with Tukey’s post hoc test.
Our findings show that female offspring exposed to heroin in utero displayed a sensitized behavioral response to heroin in adolescence. This observation correlates with other studies reporting increased reward-related behavior in animals prenatally exposed to different opioids (Castellano and Ammassari-Teule, 1984; Wu et al., 2009; Chiang et al., 2014; Wong et al., 2014). A sensitized drug response indicates drug-induced plasticity in the brain’s reward system (Kalivas and Stewart, 1991; Robinson and Berridge, 2001) and has been linked to increased risk for subsequent drug seeking and drug taking (Vezina, 2007). mAb pretreatment to heroin-exposed pregnant mice prevented behavioral sensitization to heroin in adolescent female offspring. This demonstrates that mAb administration may protect the fetus against heroin-induced persistent neuroadaptations in the reward system, and possibly prevent increased vulnerability to future drug exposure in the offspring.

Prenatal opioid exposure has also been shown to induce hyperactivity upon novelty in adolescent and adult offspring (Lasky et al., 1977; Zhu and Stadlin, 2000; Timár et al., 2010; Sithisarn et al., 2017). Interestingly, a link between an animal’s hyperactivity in a novel environment and a higher propensity for developing drug sensitization or drug self-administration has been proposed for several classes of drugs, including opioids (Piazza et al., 1989; Piazza and Le Moal, 1996; Suto et al., 2001). In addition to behavioral sensitization in the adolescent females prenatally exposed to heroin, our results also revealed increased basal activity during habituation to a novel environment. This is consistent with previous findings in adolescent rats after prenatal heroin exposure (Lasky et al., 1977; Zhu and Stadlin, 2000). In the study by Zhu and Stadlin (2000), the authors proposed that the lack of habituation reflected an impaired learning mechanism, and linked their findings to similar observations in humans. Children exposed to intrauterine opioids have an increased risk of hyperactivity and ADHD, impulsivity, and poorer learning and working memory compared with nonexposed children (Sinning, 2004; Suddelbin Wahlsen and Sarman, 2013; Levine and Woodward, 2018). We found that the hyperactivity in adolescent females exposed to prenatal heroin was prevented by maternal anti-6-AM mAb pretreatment. This further indicates that passive immunization during pregnancy may protect heroin-exposed offspring against future adverse effects, such as hyperactivity or ADHD related behavior.

The present study revealed adverse long-term behavioral effects after prenatal heroin exposure in female offspring only, in accordance with the findings by Zhu and Stadlin (2000). Sex-specific effects after exposure to intrauterine opioids have been reported previously (Vathy et al., 1995; Slamberová et al., 2001; Timár et al., 2010), and may reflect the sexual dimorphism between the male and female brain from early stages of development (Hammer, 1985; Auger et al., 2001; Armoskus et al., 2014). While our findings indicate that females are more sensitive to heroin exposure during fetal development compared with males, other studies have shown morphine-induced increases in basal activity in male offspring only (Shavit et al., 1998; Timár et al., 2010). These discrepancies imply that the outcome in offspring is highly influenced by the timing of drug exposure, dosage, and/or the type of opioid drug administered during pregnancy (Byrnes and Vassoler, 2018). However, the exact underlying mechanisms for sex-characteristic effects of prenatal opioid exposure remain unidentified.

Opioid use during pregnancy has been associated with decreased birth weight, poorer birth outcomes, and withdrawal symptoms in both human and animal neonates (Farid et al., 2008; Fodor et al., 2014; Byrnes and Vassoler, 2018). In rodents, increased USV and blood levels of stress hormones are considered as animal equivalents to certain aspects of neonatal abstinence syndrome (Barr et al., 2011). We found no effects of maternal heroin exposure on maternal weight, birth weight, or litter size. Furthermore, no significant differences in USV, blood corticosterone concentrations, or μ-opioid receptor binding in neonatal brain were found between the different treatment groups. Thus, our study demonstrates long-term behavioral changes induced by prenatal heroin exposure, without prominent effects observed in newborn pups. Of special concern is the finding that even very low heroin concentrations can promote persistent neurobiological changes expressed as adverse behavioral effects in the offspring.

The anti-6-AM mAb employed in our study belongs to the human IgG1 subclass, and was detected in both maternal and fetal mouse blood after administration to pregnant mice. Fetal blood mAb levels were 25% of maternal levels, suggesting that 6-AM sequestration in both maternal and fetal blood contributed to fetal neuroprotection, with the major effect occurring in the dam. In a study of active vaccination against nicotine, fetal serum antibody levels were reported to be 10% of the maternal concentration, suggesting limited transport of antibodies across the mouse placental barrier (Keyler et al., 2005). Endogenous IgG1 has been shown to cross the placental barrier by Fc receptor–mediated transport in both humans and rodents (Kim et al., 2009; Palmeira et al., 2012), and this mechanism is probably also involved in transfer of human IgGs across the mouse placenta. Upon administration of exogenous antibodies, there is a potential risk of inducing host immunogenic responses (Loisel et al., 2007; Overdijk et al., 2012). However, we have previously administered anti-6-AM mAb at doses up to 100 mg/kg to adult mice without any sign of adverse immunogenic effects (Bogen et al., 2014; Vello et al., 2016). Accordingly, we found no effect of the mAb on maternal weight gain, maternal behavior, or neonatal outcome during the 5-week experimental period of the present study, suggesting that the human IgG was tolerated by the mouse immune system.

Considering the increasing evidence of long-lasting neurocognitive consequences of prenatal opioid exposure, including opioid maintenance therapy (Farid et al., 2008), new strategies to treat pregnant opioid users are requested. A previous study comparing active and passive immunization against nicotine to prevent fetal drug exposure found passive immunization most efficient (Keyler et al., 2003), most likely due to difficulties in obtaining sufficient and controllable mAb levels upon active immunization. Administration of premade mAbs allows higher predictability of serum concentrations and reduces interindividual variation of mAb levels (Janda and Treweek, 2012; Zalewska-Kaszubska, 2015). The anti-6-AM mAb levels measured in pregnant females on E18 were approximately 50% of the expected levels based on our previous experiments in adult males (Kvello et al., 2016). This could be explained by changes in mAb pharmacokinetics during pregnancy, as shown by Hubbard et al. (2011b), who reported the half-life of a mAb against phencyclidine to be
reduced from 6.6 days in nonpregnant rats to 3.7 and 1.4 days on E8 and E15, respectively.

Over the past decade, mAbs have evolved from being a promising theoretical treatment to clinically approved medication for a wide range of diseases, and is currently the fastest growing group of pharmaceutical molecules (Kaifu and Nakamura, 2015). The main obstacles to implement mAbs for drug abuse treatment are high-cost production of large amounts of purified IgG, and the inconvenience of repeated administrations to sustain efficient antidrug protection (Brimijoin et al., 2013). However, long-lasting mAbs with half-lives of 3 to 4 weeks make prophylactic prevention of drug abuse feasible, at least for limited time periods in patient subgroups, such as pregnant women with a history of opioid dependence. An immunotherapeutic approach to treat pregnant heroin users could be suitable for highly motivated patients (Zalewska-Kaszubska, 2015), who wish to avoid opioids during pregnancy and need a safety net against relapse.

In conclusion, we provide evidence that maternal pretreatment with a 6-AM-specific antibody protects the fetal brain from active heroin metabolites, and thereby prevents adverse long-term behavioral effects in female adolescent offspring exposed to intrauterine heroin. To our knowledge, this is the first study demonstrating immunotherapeutic protection from persistent neuronal changes induced by prenatal drug exposure. Thus, passive immunization should be further explored as potential prophylactic treatment of pregnant opioid users susceptible to heroin relapse.

Acknowledgments
We thank Affitech Research AS for making the anti-6-AM mAb available for the research and Tove Karin Herstad for excellent technical assistance with antibody production.

Authorship Contributions
Participated in research design: Kvello, Andersen, Øiestad, Aase, Marlen, Børgen.
Conducted experiments: Kvello, Andersen, Øiestad, Steinsland, Børgen.
Contributed new reagents or analytic tools: Aase.
Performed data analysis: Kvello, Steinsland, Marlen, Børgen.
Wrote or contributed to writing of the manuscript: Kvello, Andersen, Øiestad, Steinsland, Aase, Marlen, Børgen.

References